secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001104659-24-086088
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist Q2 net loss $30.6M; cash $595.4M; JNJ-2113 Phase 3 data expected Q4 2024
--------------------------------------------------------------------------------

- Q2 net loss of $30.6M ($0.50/share) vs $38.5M loss in Q2 2023; six-month net income $176.7M from Takeda upfront.
- Cash, equivalents and marketable securities of $595.4M as of June 30, 2024; runway through end of 2027.
- JNJ-2113 Phase 3 ICONIC-LEAD and ICONIC-TOTAL in psoriasis primary endpoint completion expected Q4 2024.
- Phase 2b ANTHEM in ulcerative colitis primary endpoint completion also expected Q4 2024; Phase 3 VERIFY rusfertide topline due Q1 2025.
- Dr. Newman Yeilding appointed Chief Scientific Advisor effective August 1, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465924086088/0001104659-24-086088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465924086088/tm2419327d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-086088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer